Sonoma Pharmaceuticals, Inc. (SNOA) Amy Trombly, CEO

Sonoma Pharmaceuticalsis a global healthcare leader for developing and producing stabilizedhypochlorous acid (HOCl) products for a wide range of applications, includingwound care, eye care, nasal care, oral care, dermatological conditions, animalhealth care and non-toxic disinfectants. The company's products reduceinfections, itch, pain, scarring and harmful inflammatory responses in a safeand effective manner. In-vitro and clinical studies of hypochlorous acid (HOCl)show it to have impressive antipruritic, antimicrobial, antiviral andanti-inflammatory properties. Sonoma's stabilized HOCl immediately relievesitch and pain, kills pathogens and breaks down biofilm, does not sting orirritate skin, and oxygenates the cells in the area treated, assisting the bodyin its natural healing process. The company's products are sold either directlyor via partners in 55 countries worldwide.